On the 15th, the National Health Insurance Administration issued the “Notice Concerning the Trial Implementation of the Pre-registration System for High-Level New Technology and New Product Medical Service Price Projects”, which clearly explores the establishment of a pre-project system for medical service price projects to promote large-scale application of major innovations. In the past, new technology, new equipment, and new consumables were approved by the health department or drug supervision department before starting the price approval process. By exploring the pre-project system, the key points of price support were moved to the R&D and clinical research stages. Dong Zhaohui, Deputy Director of the Pharmaceutical Prices and Bidding and Procurement Department of the National Health Insurance Administration: The pre-project system focuses on innovation in three situations. A new technology with great clinical value and breakthroughs in diagnosis and treatment methods. New equipment to meet major clinical needs, effectively solve diagnosis and treatment problems in key areas, and improve the efficiency and accuracy of diagnosis and treatment. New consumables that fill gaps in diagnosis and treatment, mainly benefit patients, and change surgical plans. At the same time, the notice made it clear that ordinary iterative upgrade equipment, conventional reagents, and products that can be directly charged according to consumables and drugs are not within the scope of the pre-approved project.

On the 15th, the National Health Insurance Administration issued the “Notice Concerning the Trial Implementation of the Pre-registration System for High-Level New Technology and New Product Medical Service Price Projects”, which clearly explores the establishment of a pre-project system for medical service price projects to promote large-scale application of major innovations. In the past, new technology, new equipment, and new consumables were approved by the health department or drug supervision department before starting the price approval process. By exploring the pre-project system, the key points of price support were moved to the R&D and clinical research stages. Dong Zhaohui, Deputy Director of the Pharmaceutical Prices and Bidding and Procurement Department of the National Health Insurance Administration: The pre-project system focuses on innovation in three situations. A new technology with great clinical value and breakthroughs in diagnosis and treatment methods. New equipment to meet major clinical needs, effectively solve diagnosis and treatment problems in key areas, and improve the efficiency and accuracy of diagnosis and treatment. New consumables that fill gaps in diagnosis and treatment, mainly benefit patients, and change surgical plans. At the same time, the notice made it clear that ordinary iterative upgrade equipment, conventional reagents, and products that can be directly charged according to consumables and drugs are not within the scope of the pre-approved project.